Function and application of PD-1 ubiquitination agonist

Abstract

The invention belongs to the technical field of life sciences, and specifically relates to a function and application of a PD-1 ubiquitination agonist. After extensive and in-depth research, the invention finds for the first time that PD-1 has an ubiquitination phenomenon and then is degraded, so that the functions of activation, proliferation and cytokine secretion of T cells can be enhanced, thekilling function and proliferation ability of the tumor infiltrating T cells can be improved, and the tumor cells can be killed by an immune system; FBXO38 is a target that can promote PD-1 ubiquitination, the degradation of the PD-1 can be significantly promoted by promoting the expression of the FBXO38, the degradation of the PD-1 can be inhibited by inhibiting the expression of the FBXO38, andthe agonist can be used to treat autoimmune diseases. Therefore, the agonist provides strong scientific evidence for clinical immunotherapy of tumors and treatment of the autoimmune diseases from a clinical patient sample level, cell function level and molecular level.

Description

technical field [0001] The invention belongs to the technical field of life sciences, and specifically relates to the function and application of a PD-1 ubiquitination agonist. Background technique [0002] Malignant tumors are currently one of the most lethal diseases. Conventional treatment methods such as surgical resection, radiotherapy and chemotherapy are widely used in tumor treatment. However, these methods have limitations in the treatment of tumors, and it is difficult to completely cure them. Tumors, especially some metastatic malignant tumors. [0003] As the most important line of defense for human health, the immune system is responsible for not only discovering and eliminating various pathogenic microorganisms (anti-infection) and harmful substances that may be produced in the body (anti-tumor), but also avoiding damage to the body or produce autoimmune disease. The immune system has a complex regulatory network to ensure that the immune response is in a bal...

AI Technical Summary

Problems solved by technology

However, many clinical data suggest that the effective rate of PD-1 antibodies against most solid tumors is only about 20%-40%, which means that most patients still cannot benefit from immunotherapy

Images